Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 28: 2057-2067, 1982;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winkel, P.
Right arrow Articles by Sheike, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winkel, P.
Right arrow Articles by Sheike, O.

Clinical Chemistry, Vol 28, 2057-2067, Copyright © 1982 by American Association for Clinical Chemistry

Predicting recurrence in patients with breast cancer from cumulative laboratory results: a new technique for the application of time series analysis

P Winkel, MW Bentzon, BE Statland, H Mouridsen and O Sheike

We followed the cases of 26 consecutive postmenopausal patients operated on for primary breast cancer. Serum specimens were obtained each month for 1.5 years and stored at -80 degrees C until assayed for carcinoembryonic antigen (CEA) and other quantities. Ten patients developed recurrence, while 16 qualified as controls (no clinical recurrence for at least 1.7 years after the last venipuncture). Using the homeostatic autoregressive time series model, modified by us to be particularly sensitive to sustained deviations from the mean, we detected four recurrences by CEA without having any falsely positive alarms. Group-based reference limits and application of the unmodified homeostatic model were less effective (fewer detected and shorter lead time). Simulation studies, involving use of a mathematical model relating CEA concentration to tumor growth and using parameters estimated from patient data, verified this and indicated that at least five stable baseline values are needed to detect 100% of recurrences before they are detected by the group-based limit.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by the American Association for Clinical Chemistry.